TBA The Biotechnology Initiative

The Voice of Bioscience in Ontario

NEWS

SPONSORS

Flash Slideshow

 


Amorfix Appoints Dr. Philippe Couillard to its Board of Directors

TORONTO, ON, October 1, 2009 - Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, announced today that Philippe Couillard, MD, former Minister of Health and Social Services for Quebec, has been appointed to its Board of Directors.

Dr. Couillard began his career as a neurosurgeon in 1985 and served as the chief of the department of Neurosurgery at St. Luc Hospital from 1989 to 1992. From 1992 to 1996, he co-founded and ran the department of Neurosurgery in Dhahran in Saudi Arabia. On his return to Canada in 1996, Dr. Couillard became a professor in the Faculty of Medicine at the University of Sherbrooke and was both the director and chief surgeon of the department of Surgery at the Centre Hospitalier Universitaire de Sherbrooke until 2003. He was elected to the Quebec National Assembly and served as Minister of Health and Social Services of Quebec from 2003 to 2008 – making him the longest serving health minister in that province since 1958. During his term in office, Dr. Couillard directed a number of major reforms of the Quebec healthcare system and established a bi-annual Quebec-France symposium on health. Dr. Couillard is currently a senior fellow in health law at McGill University and a partner with Persistence Capital Partners, a Montreal-based private equity fund dedicated to the healthcare sector.

Graham Strachan , Chairman of the Amorfix Board of Directors, commented, "We are delighted to have Dr. Couillard join the Company's Board. Philippe’s great clinical and scientific accomplishments, combined with his senior political experience, will be a tremendous asset to Amorfix as we work toward bringing our treatments and diagnostics for brain wasting diseases successfully to market."

About Amorfix

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting brain-wasting diseases including ALS, Alzheimer’s Disease, variant Creutzfeldt-Jakob Disease (vCJD) and Cancer. Amorfix’s proprietary Epitope Protection™ (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated misfolded proteins are a common element of many brain wasting diseases and the ability to identify AMPs and understand their structure and mechanism of folding are the first steps to developing new treatments for these devastating diseases. Amorfix utilizes its computational discovery platform, ProMIS™, to predict novel Disease Specific Epitopes (“DSE”) on the molecular surface of misfolded proteins. ProMIS™ is an “in silico” rational selection approach that can be applied to any protein where the normal folding structure is at least partially known. Amorfix’s lead therapeutic programs include antibodies and vaccines to DSEs in ALS, Alzheimer’s disease and Cancer. The Company’s diagnostic programs include a blood screening test for diagnosis of vCJD and an ultrasensitive method for the detection of aggregated β-Amyloid in brain tissue of animal models of Alzheimer’s disease, months prior to plaque formation.

For more information, please contact:

Dr. George Adams
President & Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6959
Fax: (416) 847-6899
george.adams@amorfix.com

James Parsons
Chief Financial Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6929
Fax: (416) 847-6899
james.parsons@amorfix.com